Kozlova and colleagues have shown that disruption of the CIN85/PHD2 interaction using CRISPR/Cas9 editing not only led to lower levels of HIF-1α and HIF-2α, but also to significantly impaired tumor growth and migration in a breast carcinoma model (MDA-MB-231) [34]. Here, EGLN1 is linked to breast carcinoma.